COLL
$35.93+0.31 (+0.87%)
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicin...
Recent News
BrightSpring Health Services, Collegium Pharmaceutical, and Phibro Animal Health Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after easing crude oil prices helped lift investor sentiment and reduce inflation worries.
Collegium Pharmaceutical touts record 2025, sees JORNAY PM driving 2026 growth at Barclays Miami Conference
Collegium Pharmaceutical (NASDAQ:COLL) highlighted a “record-breaking” 2025 and outlined its 2026 outlook at the Barclays Miami Conference, emphasizing strong performance from newly acquired ADHD product JORNAY PM alongside what management described as a durable pain portfolio. Management recaps a
A Look At Collegium Pharmaceutical (COLL) Valuation After Recent Share Price Pressure
Stock performance snapshot and company backdrop With no single headline event driving the move, Collegium Pharmaceutical (COLL) has drawn attention after recent share price pressure, including a decline of about 24% over the past month and 29% over the past 3 months. See our latest analysis for Collegium Pharmaceutical. That recent share price pressure sits against a mixed backdrop, with a 1-year total shareholder return of 17.11% and a 3-year total shareholder return of 44.53% contrasting...
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have realized strong financial performance, and over the past six months, the industry’s 3.8% return has closely followed the S&P 500.
Collegium Pharmaceutical (COLL) Surged Following Record Quarterly Results
Third Avenue Management, a New York City-based investment firm, published its fourth-quarter 2025 investor letter for the “Third Avenue Small-Cap Value Fund. ” A copy of the letter is available for download here. In the quarter, the Fund returned 4.62%, outperforming the MSCI USA Small-Cap Value Index (the “Index”), which gained 3.13%. For the year […]